• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>ICO

ICO

  1. Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market

    Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market

  2. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

    Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.